Ticagrelor is a reversible P2Y12 platelet receptor inhibitor used in patients with coronary artery disease. Bentracimab is a monoclonal antibody that targets ticagrelor and immediately reverses its effect, allowing urgent or emergency surgery without excessive hemorrhage.

Clinical trial: REVERSE-IT


Type of monoclonal antibody: Fab fragment


Administration: intravenous infusion


Alternative approaches to ticagrelor reversal:

(1) discontinue and wait for platelet function to normalize (of limited use for urgent surgery)

(2) platelet transfusion with fresh frozen plasma


Adverse effects: thrombosis in 5%

To read more or access our algorithms and calculators, please log in or register.